Gilead Sciences filings document material events, operating results, governance matters and capital-structure disclosures for a Delaware biopharmaceutical company whose common stock trades as GILD on the Nasdaq Global Select Market. Form 8-K reports furnish quarterly and annual financial results, including GAAP and non-GAAP measures and reconciliations, and disclose completed acquisition activity affecting oncology pipeline assets.
Proxy and annual meeting filings record director elections, auditor ratification and shareholder voting outcomes. Other current reports cover executive and governance changes, Regulation FD disclosures, material agreements, and formal exhibits tied to Gilead’s virology and oncology business, including clinical or regulatory disclosure categories when they are part of the company’s public reporting.
Gilead Sciences Chief Financial Officer Andrew D. Dickinson reported an open-market sale of 3,000 shares of common stock at an average price of $132.27 per share. After this transaction, he directly holds 173,191 shares of Gilead common stock. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024, indicating the trade was scheduled in advance rather than timed discretionarily.
Gilead Sciences Chief Comm & Corp Aff Officer Johanna Mercier reported option exercises and share sales. On May 15, 2026, she exercised 25,000 non-qualified stock options at an exercise price of $66.64 per share and acquired the same number of common shares.
That day she also completed open-market sales totaling 28,000 shares of Gilead common stock in multiple trades at prices ranging from about $129.66 to $132.78 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on February 20, 2025. Following these transactions, she directly holds 125,779 common shares and retains 23,110 stock options with a $66.64 exercise price expiring on July 24, 2029.
Gilead Sciences, Inc. is conducting a primary offering of senior unsecured notes totaling $3.0 billion across four series: $500 million 4.250% due 2028, $1.0 billion 4.400% due 2029, $1.0 billion 4.600% due 2031 and $500 million 4.900% due 2034. Interest accrues from May 20, 2026 and is payable semiannually on May 20 and November 20, beginning November 20, 2026. Net proceeds are estimated at approximately $2.99 billion and will be used for general corporate purposes, potentially including acquisitions, investments and other strategic uses. The notes are senior unsecured obligations, rank pari passu with other senior unsecured debt and will not be listed on any exchange.
GILD filed a Form 144 reporting proposed sales of specified common stock. The notice lists a Stock Option Exercise of 25,000 shares dated 05/15/2026, 494 restricted shares dated 12/10/2024, and 2,506 performance shares dated 02/04/2025.
The filing also records sales by Johanna Mercier in the prior three months: 3,000 shares on 04/15/2026 ($422,880.00), 3,000 shares on 03/16/2026 ($432,690.00), and 28,000 shares on 02/17/2026 ($4,324,227.70).
Andrew Dickinson submitted a Form 144 notice indicating a proposed sale of 3,000 shares of Common Stock described as Performance Shares (issued 01/24/2023) through Morgan Stanley Smith Barney LLC. The filing also lists three recent sales of 3,000 shares each on 02/17/2026, 03/16/2026, and 04/15/2026 with reported proceeds.
Gilead Sciences, Inc. is offering multiple series of senior unsecured notes under a preliminary prospectus supplement related to an effective shelf registration. The notes will be senior unsecured obligations that rank equally with Gilead’s other senior unsecured debt, will be issued in book-entry form through DTC and are payable semiannually commencing in 2026.
The indenture permits optional redemption (including at Par Call Dates) and requires an offer to repurchase the notes at 101% of principal upon a Change of Control Triggering Event. Net proceeds are designated for general corporate purposes. The prospectus supplement incorporates certain SEC filings by reference, including the Form 10-K for the year ended and Form 10-Q for the quarter ended .
GILEAD SCIENCES, INC. filed a Form 13F reporting its institutional investment manager holdings. The report lists 6 information-table entries with a total reported market value of $2,117,784,504. The filing names Gilead Therapeutics A1 Unlimited Co as an other included manager and is signed by CFO Andrew D. Dickinson on 05-08-2026.
Gilead Sciences reported higher profit and revenue for the quarter ended March 31, 2026. Total revenues rose to $6.96 billion from $6.67 billion, driven mainly by 10% growth in HIV product sales to $5.03 billion and 37% growth in Trodelvy oncology sales to $402 million, partly offset by a 52% decline in Veklury COVID-19 sales to $144 million and lower cell therapy revenue.
Net income increased to $2.02 billion from $1.32 billion, and diluted earnings per share rose to $1.61 from $1.04, helped by higher product sales, lower acquired in‑process R&D expenses and net unrealized gains on equity securities. Operating cash flow strengthened to $2.54 billion, and the company ended the quarter with $7.63 billion in cash and cash equivalents.
Looking ahead, Gilead expects a large non‑recurring charge. Management plans to record about $11.5 billion of acquired in‑process R&D expense in the second quarter of 2026 tied to recent Arcellx, Tubulis and Ouro transactions, and indicates this will result in a net loss for both the second quarter and full year 2026 despite solid underlying operations.
Gilead Sciences reported first quarter 2026 revenue of $6.96 billion, up 4% year over year, driven by 10% HIV growth to $5.03 billion and strong contributions from Trodelvy and Livdelzi, partly offset by a 52% decline in Veklury to $144 million and softer Cell Therapy sales.
GAAP diluted EPS rose to $1.61 from $1.04, and non-GAAP diluted EPS increased to $2.03 from $1.81, helped by higher product sales, net unrealized gains on equity securities, and lower acquired IPR&D expenses.
For full year 2026, Gilead raised product sales guidance to $30.0–$30.4 billion and product sales excluding Veklury to $29.4–$29.8 billion, but now expects a GAAP diluted loss per share of $(3.25) to $(2.85) and a non-GAAP diluted loss per share of $(1.05) to $(0.65), primarily due to $11.5 billion anticipated acquired IPR&D charges and financing costs tied to the Arcellx, Ouro and Tubulis transactions.
Gilead Sciences director Jeffrey Bluestone reported new equity awards. He received 1,146 restricted stock units under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, each representing one share of common stock, and the RSUs vested immediately on April 30, 2026. He was also granted a non-qualified stock option for 4,884 shares of common stock at an exercise price of $130.84 per share, with 100% of the option vesting immediately on the same date. Following these transactions, he holds 10,066 shares of Gilead common stock directly, in addition to the option position.